| Biomarker ID | 858 |
| PMID | 22302227 |
| Year | 2012 |
| Biomarker | basic fibroblast growth factor (bFGF) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Upregulated in Treatment Group: [Treatment: 32 (25–71) Vs Control : 11 (8–14)] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-FGFR4 ligand binding and activation,Angiogenesis,Integrins in angiogenesis,Melanoma |
| Experiment | ADT Treatment Vs No Treatment |
| Type of Biomarker | Predictive |
| Cohort | 37 ADT-naïve men with locally advanced or recurrent prostate cancer. Of those, 23 initiated ADT with a gonadotropin-releasing hormone (GnRH) agonist and 14 served as nontreatment controls. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.0006 |
| Method Used | ELISA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | FGF2 |